We have evaluated whether allogeneic hematopoietic stem cell transplantation (HSCT) could induce an antitumor effect in patients with metastatic solid tumors. A total of 12 HLA-identical siblings and 6 HLA-A-, -B-and -DRb1-compatible unrelated grafts were used. Diagnoses were adenocarcinoma of kidney (n ¼ 10), colon (n ¼ 6), breast (n ¼ 1) and cholangiocarcinoma (n ¼ 1). Conditioning was fludarabine 30 mg/m 2 /day for 3 days and 2 Gy of total body irradiation. Recipients of unrelated HSCT were also given thymoglobuline and two additional days of fludarabine. The median CD34+ cell dose was 7.5 Â 10 6 / kg. Immunosuppression was mycophenolate mofetil and cyclosporin. Among all, 12 patients became complete donor chimeras within a median of 28, 29 and 65 days for B, myeloid and T cells, respectively. Two patients rejected the grafts, one developed marrow aplasia and three were mixed chimeras. The probability of grades II-IV acute graft-versus-host-disease (GVHD) was 57%. Regression of all tumor metastases was seen in one patient with colon carcinoma. Another patient with colon and two with renal carcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. Necrosis of lung metastasis was found in one further patient with renal carcinoma who died of graft-versushost-disease (GVHD). In all, 10 patients died; four of transplant-related complications, one of trauma and five of progressive disease. Thus, progression was common after allogeneic HSCT in unselected patients with advanced solid tumors. However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning. The immune system is known to induce tumor regression.
/ kg. Immunosuppression was mycophenolate mofetil and cyclosporin. Among all, 12 patients became complete donor chimeras within a median of 28, 29 and 65 days for B, myeloid and T cells, respectively. Two patients rejected the grafts, one developed marrow aplasia and three were mixed chimeras. The probability of grades II-IV acute graft-versus-host-disease (GVHD) was 57%. Regression of all tumor metastases was seen in one patient with colon carcinoma. Another patient with colon and two with renal carcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. Necrosis of lung metastasis was found in one further patient with renal carcinoma who died of graft-versushost-disease (GVHD). In all, 10 patients died; four of transplant-related complications, one of trauma and five of progressive disease. Thus, progression was common after allogeneic HSCT in unselected patients with advanced solid tumors. However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning. The immune system is known to induce tumor regression. 1 Following allogeneic hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD) has been found to contribute to an antileukemic effect. 2, 3 An alloresponse of donor T lymphocytes is most probably the cause of GVHD and the graft-versus-leukemia (GVL) effect. 4 An allogeneic graft-versus-tumor (GVT) effect has also been reported in breast and renal metastatic carcinoma. [5] [6] [7] [8] [9] When performing HSCT, lethal myeloablative conditioning to eradicate leukemia and induce marked immunosuppression to pave the way for the donor immunohematopoietic system has been the routine for several decades 10À13 . However, this approach has been challenged by using lower doses and less toxic conditioning to induce immunosuppression and take advantage of the GVT effect later rather than the antitumor effect of chemoradiotherapy. [14] [15] [16] [17] [18] [19] Inspired by the nonmyeloablative conditioning and the demonstrated allogeneic antitumor effect in renal carcinoma patients, 8, 9 we used a low-intensity conditioning protocol and included patients with not only renal but also other solid tumors, such as adenocarcinoma of colon and breast as well as cholangiocarcinoma in liver. The aim was to evaluate engraftment and complications following HSCT, and whether HSCT could induce an antitumor effect in patients with various solid tumors.
Material and methods

Patients
Between August 1999 and January 2001, 10 patients with metastatic adenocarcinoma of kidney (R1-R10), six with colon (C1-C6) and one with breast adenocarcinoma (B1) as well as one with cholangiocarcinoma in liver hilum, Klatskin tumor (L1), were treated with reduced intensity conditioning and allogeneic peripheral HSCT at Huddinge University Hospital. All 18 patients had been considered to have tumors not curable with any conventional therapy. All but two patients underwent debulking of the primary tumor and, in four patients, reduction of metastases was also done. Eight patients had been given additional prior therapy, such as cytostatics, irradiation or immunotherapy. There were eight females and 10 males with a median age of 54 (range 38-65) years and 59 (range 51-77) years, respectively. Patient and graft characteristics are shown in Table 1 .
The study was approved by the Research Ethics Committee at Huddinge University Hospital.
Conditioning
The low-intensity conditioning consisted of fludarabine 30 mg/m 2 /day for three consecutive days in patients with an HLA-identical sibling donor, and for 5 days in those with a matched unrelated donor (MUD), followed by 2 Gy of total body irradiation (TBI). 18 Antithymocyte globulin (Thymoglobuline s , IMTIX-Sangstat, Lyon, France) was given at a dose of 2 mg/kg/day for 2 days to patients with an unrelated donor (n ¼ 6). 20 
Donor selection and collection of stem cells
The selection of donors was based on HLA typing with high-resolution polymerase chain reaction-single-stranded polymorphism (PCR-SSP) for classes I and II. 21 All donors were at least HLA-A, -B and DRb1 compatible with the recipient. An HLA-matched sibling donor (n ¼ 12) was given priority but, if not available, an unrelated donor (n ¼ 6) was accepted for patients with solid tumor, where tumor response had been documented using HLA-identical siblings by us or others. 9 This was approved by the Research Ethics Committee at Huddinge University Hospital.
Peripheral blood stem cells (PBSC) were collected after G-CSF, 10 mg/kg/day, (Neupogen R , Amgen, Stockholm, Sweden) stimulation of all donors. 22 The median cell yield in grafts was 7.5 Â 10 6 CD34+ cells/kg recipient BW (range 1.7-21.8) ( Table 1) .
GVHD prophylaxis and treatment
Post-transplant immunosuppression consisted of mycophenolate mofetil, 0.5-1 g twice a day for 1-2 months. 18, 19, 23 In addition, cyclosporin (CsA) was given to all patients for at least 3 months. The CsA doses ranged between 3 and 12 mg/kg to achieve a through level of 100 ng/ml and 200 to 300 ng/ml in patients with a sibling or unrelated donor, respectively. 24, 25 Initial treatment of acute GVHD was given by prednisolone 2 mg/kg/day as early as grade I to avoid more severe GVHD. 26 
Supportive care and treatment
Prophylaxis against infections included ciprofloxacin p.o., fungillin p.o., nystatin p.o., acyclovir p.o. and trimethoprim/sulfamethoxazol p.o., according to our HSCT protocol. 24, 27 Asymptomatic cytomegalovirus (CMV) viremia, diagnosed by CMV-PCR, 28 was treated with pre-emptive therapy using oral ganciclovir or i.v. according to a randomized study. Symptomatic CMV disease was treated with i.v. ganciclovir.
Chimerism analysis
Chimerism analysis was done by collecting peripheral blood samples from the donor and recipient before transplantation, and from the recipient weekly for the first month and then every other week until complete donor chimerism (DC) was achieved. To evaluate lineage-specific chimerism, CD3-, CD19-and CD45-positive cells were selected from peripheral blood, using immunomagnetic beads (Dynal, Oslo, Norway) as previously described.
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Donor lymphocyte infusions
Donor lymphocyte infusions (DLI) were given in escalating doses, 1, 5, 10 and, 100 Â 10 6 CD3+ cells/kg, starting at 3-4 months after HSCT if the immunosuppressive therapy had been discontinued. 32 The indication for DLI was tumor progression and/or mixed chimerism (MC) in the absence of GVHD.
Definitions
Acute GVHD was graded from 0 to IV using standard criteria. 10 Chronic GVHD was evaluated in patients surviving beyond 90 days, and classified as limited or extensive, 33 and mild, moderate or severe by a responsible physician. 34 Bacteremia and fungemia were defined as a positive blood culture with bacteria or fungus, related to febrile episodes (X38.51C) during the first 3 months after HSCT. 35 CMV infection was diagnosed as an asymptomatic infection or symptomatic disease (viral syndrome, pneumonitis, hepatitis, gastroenteritis and encephalitis) as previously defined. 36 
Monitoring of the tumor status
The antitumor effect was monitored by a computer tomography (CT) of the thorax and abdomen 3, 6 and 12 months after HSCT. They were compared with the CTs obtained within 1 month prior to HSCT.
Statistical analysis
The Mann-Whitney U method was used to compare the number of days to complete DC. The probability of survival and acute GVHD were estimated using the method of Kaplan-Meyer.
Results
Engraftment and chimerism
All patients had initial engraftment and showed varying degrees of MC after HSCT (Figures 1 and 2 ). Table 2 ). Recipients of unrelated HSCT tended to have a faster engraftment of donor CD3+ cells than recipients of HSCT from HLA-identical siblings ( Table 2 , P ¼ 0.09). Two of the remaining six patients (R10 and C3) rejected the graft at 5 and 2 months, respectively. Another two patients (R1 and L1) were only MC in the T-cell fraction, but DC in the Bcell and myeloid-cell fractions at 2 months. Patient R6 was MC until 2.5 months when he developed sudden aplasia. EBV-DNA was found in the bone marrow. Patient C6 was still MC in all cell lineages at 4 months.
Hematopoietic recovery, transfusions and hemolysis
The post-transplant cytopenia was brief and mild. No patient experienced neutrophils lower than 0.5 Â 10 9 /l within the first month after HSCT (Table 3a) . During the first month, no platelet transfusion was needed, but seven patients were given from two to six erythrocyte transfusions (Table 3a) . Two patients (R6, R7) with blood groups B and A, respectively, and who were given a blood group O graft, developed hemolysis. They required erythrocyte transfusions up to 3 and 9 months after HSCT, respectively.
Hospitalization, regimen-related toxicities and infections
Most patients received treatment mainly on an outpatient basis. Mucositis was rare. Thus, a good nutritional status was maintained in most of the patients. Patient R1 died of renal insufficiency because of toxicity of ganciclovir 6 weeks after HSCT. Two patients (R5 and R6) suffered from septicemia because of Staphylococcus epidermidis and Pseudomonas aeruginosa within 3 months after HSCT. No clinically significant fungal infection was detected. CMV reactivation was diagnosed in 14 patients during the first 3 months after HSCT (Table 3a) . Four of them developed CMV disease such as fever and joint pain, but no tissue invasive disease developed.
GVHD
The cumulative incidence of grades II-IV acute GVHD was 57%. Overall grades II-IV acute GVHD occurred in 9/18 (50%) evaluable patients (Table 3b ). Two of these had grades III and IV, respectively. The incidence of GVHD II-IV was 7/12 (58%) in recipients of HLA-identical sibling stem cells compared to 2/6 (33%) using unrelated donors. HSCT=hematopoietic stem cell transplantation; Sib=HLA-identical sibling; MUD=matched unrelated donor.
Low-intensity conditioning and HSCT in patients P Hentschke et al Table 3a Lowest hemoglobin, platelet and white blood cell count, number of erythrocyte transfusions during the first month and CMV infection/disease during the first 3 months after HSCT Low-intensity conditioning and HSCT in patients P Hentschke et al Chronic GVHD of mild degree was seen in four patients among 14 evaluable patients observed more than 3 months after HSCT.
Tumor responses
Four patients were not evaluable because of rejection or death within 3 months, before the first scheduled CT. The first patient (C1) had regression of all metastases and has been reported in detail. 37 Three patients (R2, R7 and C4) had progression in the liver but regression of lung metastases. Patient R2 developed metastases in the liver, bone and lungs during the first 6 months, but the size and number of metastases in the lungs regressed during the next 6 months (Figure 3a, b) . Metastases in the liver and bone continued to progress during the same time (Figure 3c, d) . Patients C4 and R7 showed a similar progression of metastases in the liver, but partial regression in the lungs. Patient R4 had progression of abdominal metastases, but unchanged status of the majority of lung metastases on CT at 3 months. She died of severe GVHD involving the skin, gut and liver at 5 months. Autopsy showed necrosis of metastases in the lungs. Patient R8 without a demonstrable tumor prior to HSCT developed a subcutaneous metastasis of the original renal adenocarcinoma near the nephrectomy scar within 3 months. It was successfully extirpated.
Donor lymphocyte infusions (DLI)
DLI did not enhance GVHD in any patient. Seven patients were given from one to four escalating doses of DLI (Table 3b) . One of these patients (C4) showed a partial tumor response even before the first DLI was given. Tumor regression after DLI has not been documented so far in any of the seven patients observed for a median of 2 (range 1.5-9.5) months after the first DLI.
Survival rates and causes of death
As of 15 July, 2001, eight patients were alive 171-480 days after transplantation (median follow-up 275 days). The causes of death in 10 patients were a progressive disease in five, transplantation-related complications in four and head trauma at home in one patient (Table 3b ). The probability of survival at 300 days was 40% (Figure 4. ).
Discussion
The encouraging results described by Childs et al 8, 9 have aroused interest in this approach for patients with metastatic cancer with poor prognosis. Since few data are available, we report here our first 18 consecutive and unselected patients with solid tumors who had undergone HSCT. Six of them were transplanted with cells from an unrelated donor.
We used only 2 Gy of TBI as conditioning, combined with mycophenolate mofetil and cyclosporin as immunosuppression. Our first patient was considered not to tolerate cyclophosphamide combined with fludarabine. 37 Since the rejection rate, reported by McSweeney et al, 19 was 20%, we added fludarabine 30 mg/m 2 for 3 days to the regimen. The response of the tumor was dramatic in our first patient. 37 Thus, we decided to continue this protocol in subsequent patients. However, since the risk of GVHD and rejection is higher in unrelated donors, we gave, to prevent this, antithymocyte globulin and fludarabine for two more days. 13, 15, 38 Complete DC of all lymphoid cell lineages examined was seen in most patients. However, unlike the findings of Childs et al, 39 we found that B-and myeloid-cell donor chimerism occurred faster than donor T-cell chimerism. This discrepancy may be because we used milder conditioning. Furthermore, we used mycophenolate mofetil in addition to cyclosporin, while they used cyclosporin alone as GVHD prophylaxis. 9, 19, 23, 39 However, the incidence of moderate-to-severe acute GVHD was similar with both regimens, about 50%. This is higher than we have seen in our institution in patients with leukemia, using HLAidentical siblings or unrelated donors and myeloablative regimens, where the probability of acute GVHD II-IV was 11 and 15%, respectively. 24 With a less toxic regimen, we expected a lower incidence of GVHD. However, greater age in our patients may be one reason for the observed increase in acute GVHD. We can also speculate that reduced conditioning does not eliminate recipient antigen-presenting cells which may increase GVHD, as found in mice. 40 Childs et al 8, 9 reported complete tumor response in three patients and partial response in seven of 19 with renal cell carcinoma. We noted response in three of 10 with renal and two of six patients with colon carcinoma. A high overall rate of tumor progression may be expected because, when a new experimental procedure is used, it is mainly tried in those with advanced disease having a poor prognosis. Since a high tumor load may increase the risk of progression, debulking of the tumor before transplantation was done in all but two of our patients. Otherwise our patient population was unselected. Childs et al 9 also performed debulking of the primary renal carcinoma after X-ray based follow-up over time to select patients for HSCT. However, despite debulking, the tumor burden was high in our patients and they may resemble those undergoing HSCT with an advanced stage of their leukemia. Patients undergoing HSCT even with complete myeloablative therapy and advanced leukemia had a 75% or higher probability of relapse. [10] [11] [12] 41, 42 To improve the results and perhaps even have complete responses, patients should probably be selected at an earlier stage with a lower tumor burden.
Interestingly, we saw regression of metastases mainly in the lungs and lymph nodes, but not in the liver and bone. The tumor response in the lymph nodes may be expected if hematopoietic recipient cells are replaced by hematopoietic donor cells, which may also induce antitumor activity. The discrepancy between the higher response seen in the lungs than in the liver is unclear, because both organs are loaded by bone marrow-derived macrophages that could act as antigen-presenting cells for tumor and/or minor histocompatibility antigens to induce an allogeneic and antitumor effect.
So far, seven of our patients have been given DLI in one to four escalating doses. DLI in this setting was well tolerated with no GVHD and no aplasia. No beneficial effects of DLI have been seen so far, but the observation time has been relatively short. Childs et al 9 reported similar findings, but the effect of DLI seemed to be confined to one patient. One reason for the low response hitherto in our patients may be that no enhanced GVHD occurred. In patients with leukemia who responded by DLI, most developed acute and/or chronic GVHD. 32, 42 For instance, in those with CML who relapsed after HSCT, infusion induced long-lasting cytogenetic and molecular remission in 70-80%. 43 Effector mechanisms similar to GVHD are thought to act in the GVT reaction. 44 Functional GVT effector cells are either tumor-specific recognizing cell surface molecules that are unique to, or preferentially expressed on tumor cells, or allospecific recognizing structures expressed on normal and neoplastic host cells. Activated donor T cells are supposed to secrete cytokines such as IL-2, IL-3, interferon-g, tumor necrosis factor-a, which promote the production of additional cytokines and chemokines that may have a direct antitumor effect. Furthermore, they may recruit accessory cells, such as donor lymphokine-activated killer cells and NK cells, or may enhance the cytotoxic T cells involved in the GVT effect. Obviously, our patients did not develop the potential to these mechanisms because of slow T cell maturation lagging behind the myeloid cell chimerism.
It is expected that an increasing number of patients with otherwise untreatable metastatic cancer will be treated with HSCT at various institutions in the world. We are just at the beginning of what may develop into a new era for hematopoietic stem cell transplantation. The use of reduced intensity conditioning permits this treatment with an acceptable degree of toxicity to older patients having solid tumors, as found in this study with only four patients with transplant-related mortality. This agrees with previous findings, mainly in hematological malignancies. 9, [14] [15] [16] [17] [18] [19] Apart from adenocarcinoma of kidney, colon, breast and liver, HSCT may also be applied in prostate cancer, ovarian cancer, soft tissue sarcoma, melanoma and lung carcinoma. It is important that this is done in clinical trials -for instance, in collaboration with the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. With more worldwide experience, the role of HSCT in solid tumors will be established. Low-intensity conditioning and HSCT in patients P Hentschke et al
